Mesenchymal stem cells – Page 16 – Communicable Diseases Research

Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection

Article

Published on 2020-06-212022-10-29
Journal: Turkish Journal of Biology [Category] COVID-19,

Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises

Article

Published on 2020-06-202023-06-15
Journal: Stem cell reviews and reports [Category] MERS,

[키워드] Cell therapy coronavirus COVID-19 Immunotherapy Mesenchymal stem cells Natural killer cells regenerative medicine
[DOI] 10.1007/s12015-020-09994-5 PMC 바로가기 [Article Type] Article

Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID ‐19

Concise Review

Published on 2020-06-112022-10-28
Journal: Stem cells translational medicine [Category] COVID-19, MERS,

[키워드] accompanied accumulated acute respiratory distress Allogeneic ARDS Asthma Bacterial bacterial pneumonia chronic obstructive clinical trial Clinical use COPD COVID COVID‐19 COVID‐19 curative current Cytokine storm disease Diseases disorder disorders Effect effective Evidence Gleaning Idiopathic pulmonary fibrosis immunomodulatory property Influenza lack lung lung disorders mesenchymal stem cell Mesenchymal stem cells mortality rate MSC MSC therapy MSCs novel coronavirus disease outcomes pandemic Perspective preclinical data pulmonary conditions pulmonary disease pulmonary injury regenerative reported stem cell Stem cell therapy syndrome therapeutic therapeutic use therapy
[DOI] 10.1002/sctm.20-0186 PMC 바로가기 [Article Type] Concise Review

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

급성호흡곤란증후군의 간엽줄기세포치료제: 기초부터 임상까지

Review

Published on 2020-06-092022-09-10
Journal: Protein & Cell [Category] MERS, SARS, 비임상,

[키워드] 2019 novel coronavirus 2019 novel coronavirus disease acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alveolar fluid clearance anti-apoptotic Anti-inflammatory approaches ARDS Bacterial breath caused Cell cell damage Cell therapy China clinical study clinics coronavirus coronavirus disease COVID-19 COVID-19 patient develop disease disrupt distal Effects Efficacy ENhance epithelial epithelial cell event Extracellular vesicles Factor high mortality intrinsic limit lung mechanism mesenchymal stem cell Mesenchymal stem cells morbidity MSC MSC therapy multiple organ failure Novel coronavirus novel coronavirus disease occurred optimization Organ failure organ injury paracrine pathophysiological patients with ARDS Pneumonia promote pulmonary endothelial respiratory respiratory distress SARS-CoV-2 SARS-CoV-2-infected patient SARS-CoV-2-infected patients severe acute respiratory syndrome Coronavirus severe pneumonia stem cell supportive care survival syndrome therapeutic therapy variety
[DOI] 10.1007/s13238-020-00738-2 PMC 바로가기 [Article Type] Review

Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China

Article

Published on 2020-06-092022-10-04
Journal: Virus research [Category] SARS, 치료법, 치료제,

[키워드] ACE2, angiotensin converting enzyme II ACE2angiotensin converting enzyme II activities acute respiratory distress syndrome Adverse reactions angiotensin converting enzyme II ARDS, acute respiratory distress syndrome ARDSacute respiratory distress syndrome articles Biological Biological products C-reactive protein cellular Characteristics Chemical drugs China China National Knowledge Infrastructure Chinese chronic obstructive pulmonary disease clinical trial clinical trials CNKI CNKI, China National Knowledge Infrastructure CNKIChina National Knowledge Infrastructure convalescent plasma COPD, Chronic obstructive pulmonary disease COPDchronic obstructive pulmonary disease Coronavirus disease 2019 COVID-19 COVID-19, Coronavirus disease 2019 COVID-19coronavirus disease 2019 CP, convalescent plasma CPconvalescent plasma CRP, C-reactive protein CRPC-reactive protein database dengue virus DENV, dengue virus DENVdengue virus drug drugs EC50, half effective concentration EC50half effective concentration effective drugs Effects Efficacy and safety Fangfeng Tongsheng Pill FFTS, Fangfeng Tongsheng Pill FFTSFangfeng Tongsheng Pill filtered GA, glycyrrhizic acid GAglycyrrhizic acid glycyrrhizic acid Government half effective concentration Health HIV, Human immunodeficiency virus HIVhuman immunodeficiency virus HSBD, Huashi Baidu Prescription HSBDHuashi Baidu Prescription Huashi Baidu Prescription Human immunodeficiency virus Huoxiang Zhengqi HXZQ, Huoxiang Zhengqi HXZQHuoxiang Zhengqi IFN-α, interferon-α IFN-αinterferon-α indications Infrastructure ingredient injection Interferon-α JHQG, Jinhua Qinggan Granule JHQGJinhua Qinggan Granule Jiedu Capsule Jinhua Qinggan Granule large sample LHQW, Lianhua Qingwen Capsule LHQWLianhua Qingwen Capsule Lianhua Qingwen capsule medication MERS-CoV, Middle East respiratory syndrome coronavirus MERS-CoVmiddle east respiratory syndrome coronavirus Mesenchymal stem cells Middle East respiratory syndrome Coronavirus MNV, murine norovirus MNVmurine norovirus MSCs, mesenchymal stem cells MSCsmesenchymal stem cells murine norovirus natural killer NCP, novel coronavirus pneumonia NCPnovel coronavirus pneumonia NK, natural killer NKnatural killer Novel coronavirus novel coronavirus pneumonia pharmacological Pneumonia Potential QFPD, Qingfei Paidu Decoction QFPDQingfei Paidu Decoction Qingfei Paidu decoction Randomized controlled trials RCTs, randomized controlled trials RCTsrandomized controlled trials researcher respiratory syncytial virus ribofuranosyl-5′-triphosphate RSV, respiratory syncytial virus RSVrespiratory syncytial virus RTP, ribofuranosyl-5′-triphosphate RTPribofuranosyl-5′-triphosphate SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2severe acute respiratory syndrome coronavirus 2 SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoVsevere acute respiratory syndrome coronavirus searched severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Shufeng SFJD, Jiedu Capsule Shufeng SFJDJiedu Capsule stem cells TCM TCMs, traditional Chinese medicines TCMstraditional Chinese medicines therapeutic effect TJQW, Toujie Quwen Granule TJQWToujie Quwen Granule Toujie Quwen granule Traditional Chinese medicine traditional Chinese medicines treat Treatment Vaccines XFBD, Xuanfei Baidu Decoction XFBDXuanfei Baidu Decoction Xuanfei Baidu Decoction
[DOI] 10.1016/j.virusres.2020.198057 PMC 바로가기 [Article Type] Article

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 active malignancy acute respiratory distress syndrome Administered administration age approval approved ARDS assessment automated Berlin blinded Cell cell suspension cellular changes in chronic liver disease class clinical Clinical diagnosis Clinical outcome clinical outcomes clinical trial comparator Compliance conducted control group Controlled trial COVID 19 COVID-19 COVID-19 pandemic declined defined described determine diagnosis of COVID-19 dissemination Donor Dose escalation driving Effect Efficacy element eligible Elizabeth enrolled ethics committee EudraCT excluded facilitate failure fixed dose hospital ICU incidence Inclusion increase in index individual information infusion intensive care unit Intervention Invasive mechanical ventilation investigator King’s College London London Mesenchymal stem cells Mesenchymal stromal cells MHRA moderate Mortality MSC MSCs NIHR number objective open label Other outcome pandemic PaO participant Patient patient population patients with ARDS PCR test PF ratio Phase 1 Phase 2 Placebo placebo-controlled protocol protocol amendment Public randomised randomised controlled trial REC receiving recruited recruitment repair reported Research respiratory Resuscitation Sample size secondary Secondary objective Secondary outcomes Serious Adverse Events severe ARDS single intravenous infusion SOFA solution Standard steering committee stratified stromal cell Study protocol Therapeutics therapy trauma Treatment Trial triple blinded Trust umbilical United Kingdom university Venous Thromboembolism Ventilation verbal Volume web-based randomisation system website WHO Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter

Perspective of placenta derived mesenchymal stem cells in acute liver failure

Review

Published on 2020-05-242023-08-30
Journal: Cell & Bioscience [Category] E형 간염,

[키워드] acute liver failure Cell therapy Mesenchymal stem cells Placenta
[DOI] 10.1186/s13578-020-00433-z PMC 바로가기 [Article Type] Review

Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury

Review

Published on 2020-05-242022-10-29
Journal: Stem Cell Research & Therapy [Category] COVID-19, SARS,

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

코로나19 환자를 위한 지방유래 중간엽줄기세포의 임상적 사용 근거

Review

Published on 2020-05-182022-09-10
Journal: Journal of Translational Medicine [Category] MERS, SARS, 비임상,

[키워드] acute respiratory distress acute respiratory distress syndrome administration alveolar fluid clearance animal model animal models antimicrobial ARDS ASC benefit breath capital city Cell China Clinical studies clinical study Clinical use Comorbidity coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 outbreak COVID-19 patient Critical demonstrated distress edema effective Ex vivo Fever global pandemic globe greater Health Organization healthcare high mortality rate hospital resources human clinical trials human lung hypoxia illness immune response immune responses immunomodulatory activities in some in vivo Inflammation inhibit intravenous Intravenous administration intravenous route lead Local lung lung damage Lungs majority Mesenchymal stem cells molecules morbidity morbidity and mortality MSC MSCs multi-organ failure Multiple Novel coronavirus older patients Pain Patient patient mortality per day Pneumonia pulmonary disease Pulmonary edema Pulmonary function rationale reduce reduced respiratory respiratory distress respiratory symptoms risk Safe SARS-CoV-2 SARS-COV-2 infection severe disease Severe respiratory distress stem cell stem cells syndrome therapeutic option therapy Travel Treatment treatment of COVID-19 Viral viral outbreak viral respiratory with COVID-19 World Health Organization Wuhan
[DOI] 10.1186/s12967-020-02380-2 PMC 바로가기 [Article Type] Review

Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

Perspective

Published on 2020-04-092022-10-31
Journal: Cells [Category] COVID-19,